FAP and neoplasm: In recent decades, immunotherapy and the treatment with CAR T cells in particular have become a central focus for engaging the immune system in the fight against cancer, producing remarkable preclinical and clinical progress.[43, 44, 45, 46] To visualize and evaluate the infiltration and cytotoxic ability of the CAR T cells against solid tumors surrounded by physical barriers and FAP‐mediated immune suppression in vitro, we further design the therapeutic trials with dual targeting against PSCA and FAP antigens using our microphysiological tumor model.